IRIS Institutional Research Information System - OPENBS Open Archive UniBS

CAROSI, Giampiero
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.419
AS - Asia 11.553
EU - Europa 8.807
SA - Sud America 2.250
AF - Africa 221
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 22
Totale 44.299
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.116
CN - Cina 4.254
SG - Singapore 3.814
UA - Ucraina 2.843
BR - Brasile 1.916
HK - Hong Kong 1.397
DE - Germania 1.348
IT - Italia 1.316
FI - Finlandia 752
VN - Vietnam 645
FR - Francia 572
GB - Regno Unito 513
TR - Turchia 461
IE - Irlanda 446
RU - Federazione Russa 441
IN - India 365
SE - Svezia 165
CA - Canada 138
PL - Polonia 137
BD - Bangladesh 134
AR - Argentina 114
MX - Messico 105
IQ - Iraq 73
ZA - Sudafrica 63
PK - Pakistan 60
EC - Ecuador 59
BE - Belgio 51
ID - Indonesia 50
CO - Colombia 44
JP - Giappone 42
NL - Olanda 41
AT - Austria 36
VE - Venezuela 36
MA - Marocco 35
UZ - Uzbekistan 35
ES - Italia 34
SA - Arabia Saudita 34
AE - Emirati Arabi Uniti 26
AU - Australia 25
KE - Kenya 24
MU - Mauritius 23
IR - Iran 22
LT - Lituania 21
EU - Europa 20
PY - Paraguay 20
CL - Cile 19
MY - Malesia 18
CZ - Repubblica Ceca 17
UY - Uruguay 17
EG - Egitto 16
JO - Giordania 14
NG - Nigeria 14
PE - Perù 14
IL - Israele 13
AZ - Azerbaigian 11
JM - Giamaica 11
DZ - Algeria 10
HN - Honduras 9
OM - Oman 9
PH - Filippine 9
PT - Portogallo 9
TN - Tunisia 9
BO - Bolivia 8
BF - Burkina Faso 7
CR - Costa Rica 7
QA - Qatar 7
DO - Repubblica Dominicana 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LB - Libano 6
PA - Panama 6
RO - Romania 6
AL - Albania 5
BG - Bulgaria 5
BH - Bahrain 5
CH - Svizzera 5
GR - Grecia 5
HU - Ungheria 5
NI - Nicaragua 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
AM - Armenia 4
ET - Etiopia 4
GT - Guatemala 4
KR - Corea 4
LK - Sri Lanka 4
LV - Lettonia 4
NP - Nepal 4
PS - Palestinian Territory 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
GE - Georgia 3
GY - Guiana 3
HR - Croazia 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
MN - Mongolia 3
AO - Angola 2
Totale 44.263
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.189
Fairfield 2.160
Jacksonville 2.081
Singapore 2.013
Ashburn 1.635
Hong Kong 1.395
Houston 1.203
Wilmington 1.143
Ann Arbor 1.023
Cambridge 951
Chandler 944
Nanjing 839
Seattle 810
Princeton 807
The Dalles 769
Beijing 600
San Jose 568
Dublin 443
New York 390
Istanbul 358
Lauterbourg 358
Helsinki 309
Los Angeles 291
Nanchang 290
Ho Chi Minh City 237
Buffalo 220
Des Moines 205
Shenyang 200
Moscow 189
São Paulo 176
Hebei 175
Changsha 174
Milan 158
San Diego 147
Tianjin 141
Warsaw 131
Jiaxing 130
Jinan 130
Dearborn 119
Hanoi 116
Munich 104
Kunming 97
Shanghai 95
Hangzhou 83
Verona 79
San Francisco 71
Dallas 67
Lancaster 64
Redondo Beach 64
Chicago 61
Rio de Janeiro 59
Brescia 58
Kocaeli 56
Toronto 56
Zhengzhou 55
Orem 53
Santa Clara 53
Brussels 51
Guangzhou 47
Lanzhou 47
London 45
Nuremberg 44
Rome 44
Mexico City 41
Ningbo 41
Tokyo 39
Boardman 38
Turku 38
Belo Horizonte 36
Brooklyn 34
Council Bluffs 34
Tashkent 34
Montreal 33
Taizhou 32
Frankfurt am Main 30
Johannesburg 30
Curitiba 29
Washington 29
Leawood 28
Campinas 27
Da Nang 27
Denver 27
Brasília 26
Manchester 26
Norwalk 25
Porto Alegre 25
Stockholm 25
Baghdad 24
Chennai 24
Haikou 24
Haiphong 24
Pune 24
Atlanta 23
Biên Hòa 23
Guarulhos 23
Phoenix 23
Nairobi 21
Ribeirão Preto 21
Mumbai 20
Quito 20
Totale 28.718
Salva come PNG Salva come JPEG
Nome #
Cos’è la Medicina Tropicale 250
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA 248
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 224
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 208
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 200
Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons 200
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 197
Hepatitis C infection influence on immune recovery in HIV-positive patients on successful HAART: The role of genotype 3 190
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 182
HIV-associated asymmetric lipodystrophy syndrome 180
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 176
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 176
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 175
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 175
Trigger-oriented HIV testing at Internal Medicine hospital Departments in Northern Italy: an observational study (Fo.C.S. Study) 173
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 172
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 171
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 171
Malaria and anaemia in pregnant women in urban Zanzibar, Tanzania. 170
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 167
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 167
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 166
Accidental and transfusion malaria in Italy 165
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 165
A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009 165
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 165
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 162
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 161
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 160
HYALURONIC ACID AND LIVER STIFFNESS REDUCTION IN HIV-HEPATITIS-C (HCV) COINFECTED PATIENTS TREATED WITH A CCR5 INHIBITOR MARAVIROC (MVC) IN A RANDOMIZED CONTROLLED TRIAL (MAICOL STUDY-48-WEEK ANALYSIS) 159
Key Questions in antiretroviral therapy: Italian Consensus Workshop (2005) 158
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 158
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 157
Long-Term Response in Patients Receiving Haart Including Nelfinavir: Experience from Two Italian Centers 154
Access to antiretroviral therapy and disease progression in HIV+ migrants in Brescia, Italy 153
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 153
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 153
Access site-related infection in dialysis: the AStRID project: a multicenter prospective Italian study. 153
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 153
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 153
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 153
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 152
Filariasis in travelers presenting to the Geosentinel Surveillance Network 151
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. 151
Caratteri generali dei protozoi patogeni per l’uomo e delle infezioni protozoarie umane 150
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 149
Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients 149
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 149
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis 148
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction 148
STI epidemics in the Indian Ocean Region: can the phase be assessed? 147
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 147
Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. 147
Adherence to surgical site infection guidelines in Italian cardiac surgery units. 147
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study 147
Analisi estensiva di sequenza dei geni della trascrittasi inversa e della proteasi di HIV-1 in una coorte clinica di pazienti HIV positivi NAIVE per la terapia antiretrovirale. 146
Fatal disseminated toxoplasmosis during primary HIV infection. 145
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 145
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 144
Characteristics of schistosomiasis in travelers reported to the GeoSentinel Surveillance Network 1997-2008 143
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. 143
Interleukin-2 therapy in patients with HIV infection 143
High prevalence of radiological vertebral fractures in HIV-infected males 143
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 142
Dermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel Surveillance Network 141
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 141
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 141
VAGINAL COLONIZATION WITH CANDIDA SPP IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED WOMEN: A COHORT STUDY 139
Multicenter GeoSentinel analysis of rickettsial diseases in international travelers, 1996-2008 138
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 137
Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of Foscarnet versus Ganciclovir. 136
Towards HCV extinction with modern HCV treatment? “Yes we can!” 136
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 135
Malaria and HIV in adults: When the parasite runs into the virus 135
Baggage Malaria in Italy: Cryptic Malaria explained? 134
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. 134
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. 134
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial 134
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis 134
Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma 134
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 133
Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. 133
HIV-related liver disease: ARV drugs, coinfection, and other risk factors. 133
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 133
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 132
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 132
Animal-associated exposure to rabies virus among travelers, 1997–2012 132
Il panorama internazionale dell’epidemia : il rischio di AIDS nel Viaggiatore Internazionale 131
Risk factors for myocardial infarction in HIV positive patients 131
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 131
Polymorphic immune restoration syndrome after effective HAART 131
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 130
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 129
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions 129
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 128
Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006 128
Anti-viral potency of HAART regimens and clinical success are not strictly coupled in real life conditions. Evidence from the MASTER-1 Study 128
Mortality for liver disease in patients with HIV infection: a cohort study 128
Drug-specific risk of adverse events onset related to HAART in a resource-limited setting from 2001 to 2009: the experience of 3 medical centers in Burkina Faso 128
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 127
Totale 15.304
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.761
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021983 0 0 0 0 0 0 0 0 0 339 529 115
2021/20222.828 125 538 11 185 31 170 94 190 168 433 282 601
2022/20232.769 457 24 31 232 268 820 3 272 424 25 86 127
2023/20242.154 138 68 128 149 82 370 57 53 663 23 17 406
2024/20255.883 26 18 28 594 866 515 679 186 620 362 1.212 777
2025/202610.247 1.085 1.626 850 1.711 850 694 1.722 430 654 625 0 0
Totale 44.709